[胃肠道疾病患者肿瘤相关胰蛋白酶抑制剂（TATI）的测定。初步数据]

[Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].

作者信息

Piantino P, Mosso R, Polloni R, Cerchier A, Gennaretti G, Daziano E

机构信息

Divisione di Gastroenterologia, Ospedale Maggiore San Giovanni Battista Molinette, Torino.

出版信息

Minerva Med. 1989 Mar;80(3):199-203.

PMID:2717042

Abstract

Tumor-associated trypsin inhibitor (TATI) is a 6 K dalton protease inhibitor, that was isolated from urine of a patient with ovarian cancer. In our experience, mean serum level of TATI in healthy subjects (n. 120), is 13 micrograms/l (range 5.1-42 micrograms/l). The cut-off point is established in 32 micrograms/l (mean +/- 3 SD). We have examined 357 patients with gastrointestinal diseases: 98 gastric cancer, 50 colon cancers, 52 pancreatic cancers, 32 chronic pancreatitis, 38 IBD, 28 colon polyps, 40 gastric ulcers and 25 non-neoplastic biliary tree diseases. TATI may be a good tumor marker only in gastric cancer. Elevated levels of TATI also occur in obstructive hepatobiliary disease and active pancreatitis or IBD.

摘要

肿瘤相关胰蛋白酶抑制剂（TATI）是一种6千道尔顿的蛋白酶抑制剂，它是从一名卵巢癌患者的尿液中分离出来的。根据我们的经验，健康受试者（n = 120）的血清TATI平均水平为13微克/升（范围为5.1 - 42微克/升）。临界值设定为32微克/升（均值±3标准差）。我们检查了357例胃肠道疾病患者：98例胃癌、50例结肠癌、52例胰腺癌、32例慢性胰腺炎、38例炎症性肠病、28例结肠息肉、40例胃溃疡和25例非肿瘤性胆道疾病。TATI可能只是胃癌的一种良好肿瘤标志物。TATI水平升高也见于梗阻性肝胆疾病以及活动性胰腺炎或炎症性肠病。